COO
Price
$63.57Alerts
Change
-$0.36 (-0.56%)
Updated
Nov 10 closing price
Capitalization
11.86B
22 days until earnings call
Intraday BUY SELL Signals
RMD
Price
$234.11Alerts
Change
-$1.63 (-0.69%)
Updated
Nov 10 closing price
Capitalization
33.94B
78 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COO vs RMD

COO vs RMD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COO vs. RMD commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and RMD is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for COO with price predictions
Nov 10, 2026

COO in -3.20% downward trend, sliding for three consecutive days on November 06, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where COO declined for three days, in 202 of 334 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for COO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 12 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 43%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 63 cases where COO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.

COO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on COO as a result. In 41 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.

COO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for COO crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in 152 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

The Aroon Indicator entered an Uptrend today. In 115 of 222 cases where COO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. COO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.424) is normal, around the industry mean (4.964). P/E Ratio (21.283) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.532) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.526) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RMD with price predictions
Nov 10, 2026

RMD in downward trend: price may drop because broke its higher Bollinger Band on October 15, 2026

RMD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 32 of the 42 cases the stock fell afterwards. This puts the odds of success at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RMD moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 24 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RMD as a result. In 64 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

The Moving Average Convergence Divergence Histogram (MACD) for RMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 29 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 57 cases where RMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

RMD moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RMD crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

The 50-day moving average for RMD moved above the 200-day moving average on October 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMD advanced for three days, in 181 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 133 of 218 cases where RMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. RMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.154) is normal, around the industry mean (4.964). P/E Ratio (22.474) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (5.896) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
COO vs RMD: Fundamental Ratings
COO
RMD
OUTLOOK RATING
1..100
7981
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8040
PRICE GROWTH RATING
1..100
4948
P/E GROWTH RATING
1..100
8561
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COO's Valuation (59) in the Medical Specialties industry is in the same range as RMD (66). This means that COO’s stock grew similarly to RMD’s over the last 12 months.

COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RMD (100). This means that COO’s stock grew similarly to RMD’s over the last 12 months.

RMD's SMR Rating (40) in the Medical Specialties industry is somewhat better than the same rating for COO (80). This means that RMD’s stock grew somewhat faster than COO’s over the last 12 months.

RMD's Price Growth Rating (48) in the Medical Specialties industry is in the same range as COO (49). This means that RMD’s stock grew similarly to COO’s over the last 12 months.

RMD's P/E Growth Rating (61) in the Medical Specialties industry is in the same range as COO (85). This means that RMD’s stock grew similarly to COO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COORMD
RSI
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
56%
Bullish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
46%
Bearish Trend 1 day ago
69%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
59%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 23 days ago
56%
Bullish Trend 21 days ago
57%
Declines
ODDS (%)
Bearish Trend 6 days ago
60%
Bearish Trend 6 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
61%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (COO: $63.57 vs. RMD: $234.11)
Brand notoriety: COO and RMD are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: COO: 34% vs. RMD: 88%
Market capitalization -- COO: $11.86B vs. RMD: $33.94B
COO [@Pharmaceuticals: Other] is valued at $11.86B. RMD’s [@Pharmaceuticals: Other] market capitalization is $33.94B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COO’s FA Score shows that 0 FA rating(s) are green while RMD’s FA Score has 0 green FA rating(s).

  • COO’s FA Score: 0 green, 5 red.
  • RMD’s FA Score: 0 green, 5 red.
According to our system of comparison, RMD is a better buy in the long-term than COO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COO’s TA Score shows that 5 TA indicator(s) are bullish while RMD’s TA Score has 6 bullish TA indicator(s).

  • COO’s TA Score: 5 bullish, 4 bearish.
  • RMD’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, both COO and RMD are a good buy in the short-term.

Price Growth

COO (@Pharmaceuticals: Other) experienced а +4.50% price change this week, while RMD (@Pharmaceuticals: Other) price change was +3.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.44%. For the same industry, the average monthly price growth was +4.11%, and the average quarterly price growth was +16.86%.

Reported Earning Dates

COO is expected to report earnings on Dec 03, 2026.

RMD is expected to report earnings on Jan 28, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (+4.44% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

COO and

Correlation & Price change

A.I.dvisor indicates that over the last year, COO has been loosely correlated with A. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COO
1D Price
Change %
COO100%
-0.56%
A - COO
50%
Loosely correlated
-1.27%
BDX - COO
50%
Loosely correlated
-1.23%
ICUI - COO
49%
Loosely correlated
+1.82%
SOLV - COO
47%
Loosely correlated
-0.39%
DHR - COO
46%
Loosely correlated
+0.42%
More

RMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RMD has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then ISRG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RMD
1D Price
Change %
RMD100%
-0.69%
ISRG - RMD
47%
Loosely correlated
-2.28%
BDX - RMD
46%
Loosely correlated
-1.23%
BAX - RMD
44%
Loosely correlated
+0.04%
SOLV - RMD
44%
Loosely correlated
-0.39%
COO - RMD
40%
Loosely correlated
-0.56%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MANH257.545.82
+2.31%
Manhattan Associates
XNCR39.390.80
+2.07%
Xencor
HIHO0.850.01
+1.70%
Highway Holdings Limited
CODA8.970.14
+1.59%
Coda Octopus Group
RZLV1.39-0.03
-2.11%
Rezolve AI PLC